This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test
by Zacks Equity Research
GRAL submits final FDA PMA module for the Galleri MCED test, reaching a milestone in broader cancer screening and potential public health impacts.
BSXPositive Net Change ATRCNegative Net Change VCYTNegative Net Change GRALNegative Net Change
medical medical-devices
SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval
by Zacks Equity Research
Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.
BSXPositive Net Change IDXXNegative Net Change STEPositive Net Change SENSPositive Net Change
medical medical-devices
Can Operational Execution Support DaVita's Q4 Performance?
by Zacks Equity Research
DVA's fourth-quarter 2025 performance is likely to have gained from technology upgrades, cost control and seasonal boosts despite ongoing volume headwinds.
DVAPositive Net Change ELANNegative Net Change OPCHPositive Net Change AVAHPositive Net Change
earnings medical medical-devices
SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption
by Zacks Equity Research
SYK shares rise after fourth-quarter EPS and sales top estimates, fueled by double-digit organic growth and strong adoption of its Mako platform.
BSXPositive Net Change SYKPositive Net Change ATRCNegative Net Change PAHCPositive Net Change
earnings medical medical-devices
Simmons First National (SFNC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SFNCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy First Bancorp (FBP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FBPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Kimball Electronics Gears Up to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Weakness across the automotive and industrial segments is likely to have more than offset the benefits of strong performance at KE's medical division in Q2.
MCHPNegative Net Change LSCCNegative Net Change KENegative Net Change NETNegative Net Change
computers earnings medical medical-devices tech-stocks
HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash
by Zacks Equity Research
Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth.
ISRGNegative Net Change HOLXNegative Net Change VEEVNegative Net Change VCYTNegative Net Change
earnings medical medical-devices
Bull of the Day: Intuitive Surgical (ISRG)
by Tracey Ryniec
Never bet against the da Vinci surgical system.
ISRGNegative Net Change
medical-devices robotics
Reasons to Retain Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS shows solid 3Q25 momentum from SNS and PMR growth, aided by M&A and cost cuts, even as tariffs and FX volatility linger.
BSXPositive Net Change ATRCNegative Net Change VCYTNegative Net Change AVNSPositive Net Change
medical medical-devices